Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity
Authors
Keywords
-
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 287, Issue 38, Pages 31983-31993
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2012-07-27
DOI
10.1074/jbc.m112.374751
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma
- (2012) P.-C. Tsai et al. CLINICAL CANCER RESEARCH
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas
- (2011) T. E. Witzig et al. BLOOD
- Direct Effect of Rituximab in B-Cell-Derived Lymphoid Neoplasias: Mechanism, Regulation, and Perspectives
- (2011) C. Bezombes et al. MOLECULAR CANCER RESEARCH
- Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance
- (2010) C. Henry et al. BLOOD
- Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity
- (2010) J. Bil et al. BLOOD
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
- (2010) S. A. Beers et al. BLOOD
- Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
- (2010) Magdalena Winiarska Frontiers in Bioscience-Landmark
- Improvement of Rituximab Efficiency in Chronic Lymphocytic Leukemia by CpG-Mediated Upregulation of CD20 Expression Independently of PU.1
- (2009) Amani Mankaï et al. Annals of the New York Academy of Sciences
- Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
- (2009) J. Hiraga et al. BLOOD
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
- (2008) R. Lapalombella et al. BLOOD
- Purine-Rich Box-1-Mediated Reduced Expression of CD20 Alters Rituximab-Induced Lysis of Chronic Lymphocytic Leukemia B Cells
- (2008) A. Mankai et al. CANCER RESEARCH
- Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy
- (2008) Akiko Miyagi Maeshima et al. CANCER SCIENCE
- Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
- (2008) M. S. Czuczman et al. CLINICAL CANCER RESEARCH
- Internalisation of uncross-linked rituximab is not essential for the induction of caspase-independent killing in Burkitt lymphoma cell lines
- (2008) Julie Turzanski et al. LEUKEMIA & LYMPHOMA
- Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20
- (2008) Magdalena Winiarska et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started